These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 38368930)

  • 1. VPS35 and retromer dysfunction in Parkinson's disease.
    Rowlands J; Moore DJ
    Philos Trans R Soc Lond B Biol Sci; 2024 Apr; 379(1899):20220384. PubMed ID: 38368930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VPS35, the Retromer Complex and Parkinson's Disease.
    Williams ET; Chen X; Moore DJ
    J Parkinsons Dis; 2017; 7(2):219-233. PubMed ID: 28222538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of
    Sargent D; Moore DJ
    Int Rev Mov Disord; 2021; 2():221-244. PubMed ID: 35497708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the contributions of VPS35 and the retromer in neurodegenerative disease.
    Williams ET; Chen X; Otero PA; Moore DJ
    Neurobiol Dis; 2022 Aug; 170():105768. PubMed ID: 35588987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson's disease.
    Chen X; Tsika E; Levine N; Moore DJ
    Mol Neurodegener; 2023 Aug; 18(1):51. PubMed ID: 37542299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formation of retromer transport carriers is disrupted by the Parkinson disease-linked Vps35 D620N variant.
    Cui Y; Yang Z; Flores-Rodriguez N; Follett J; Ariotti N; Wall AA; Parton RG; Teasdale RD
    Traffic; 2021 Apr; 22(4):123-136. PubMed ID: 33347683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer.
    Follett J; Norwood SJ; Hamilton NA; Mohan M; Kovtun O; Tay S; Zhe Y; Wood SA; Mellick GD; Silburn PA; Collins BM; Bugarcic A; Teasdale RD
    Traffic; 2014 Feb; 15(2):230-44. PubMed ID: 24152121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease-linked
    Chen X; Kordich JK; Williams ET; Levine N; Cole-Strauss A; Marshall L; Labrie V; Ma J; Lipton JW; Moore DJ
    Proc Natl Acad Sci U S A; 2019 Mar; 116(12):5765-5774. PubMed ID: 30842285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on cellular and molecular determinants of Parkinson's disease with emphasis on the role of the retromer complex.
    Macías-Calvio V; Fuentealba LM; Marzolo MP
    J Neurosci Res; 2021 Jan; 99(1):163-179. PubMed ID: 32633426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retromer binding to FAM21 and the WASH complex is perturbed by the Parkinson disease-linked VPS35(D620N) mutation.
    McGough IJ; Steinberg F; Jia D; Barbuti PA; McMillan KJ; Heesom KJ; Whone AL; Caldwell MA; Billadeau DD; Rosen MK; Cullen PJ
    Curr Biol; 2014 Jul; 24(14):1670-1676. PubMed ID: 24980502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the VPS35 D620N mutation in Parkinson's disease.
    Mohan M; Mellick GD
    Parkinsonism Relat Disord; 2017 Mar; 36():10-18. PubMed ID: 27964832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.
    Tsika E; Glauser L; Moser R; Fiser A; Daniel G; Sheerin UM; Lees A; Troncoso JC; Lewis PA; Bandopadhyay R; Schneider BL; Moore DJ
    Hum Mol Genet; 2014 Sep; 23(17):4621-38. PubMed ID: 24740878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting.
    Williams ET; Glauser L; Tsika E; Jiang H; Islam S; Moore DJ
    Hum Mol Genet; 2018 Sep; 27(18):3189-3205. PubMed ID: 29893854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endosomal traffic and glutamate synapse activity are increased in VPS35 D620N mutant knock-in mouse neurons, and resistant to LRRK2 kinase inhibition.
    Kadgien CA; Kamesh A; Milnerwood AJ
    Mol Brain; 2021 Sep; 14(1):143. PubMed ID: 34530877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy.
    Zavodszky E; Seaman MN; Moreau K; Jimenez-Sanchez M; Breusegem SY; Harbour ME; Rubinsztein DC
    Nat Commun; 2014 May; 5():3828. PubMed ID: 24819384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contributions of VPS35 Mutations to Parkinson's Disease.
    Rahman AA; Morrison BE
    Neuroscience; 2019 Mar; 401():1-10. PubMed ID: 30660673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of VPS35 in the Pathobiology of Parkinson's Disease.
    Sassone J; Reale C; Dati G; Regoni M; Pellecchia MT; Garavaglia B
    Cell Mol Neurobiol; 2021 Mar; 41(2):199-227. PubMed ID: 32323152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VPS35 in Dopamine Neurons Is Required for Endosome-to-Golgi Retrieval of Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is Critical for α-Synuclein Degradation and Prevention of Pathogenesis of Parkinson's Disease.
    Tang FL; Erion JR; Tian Y; Liu W; Yin DM; Ye J; Tang B; Mei L; Xiong WC
    J Neurosci; 2015 Jul; 35(29):10613-28. PubMed ID: 26203154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VPS35 pathogenic mutations confer no dominant toxicity but partial loss of function in Drosophila and genetically interact with parkin.
    Malik BR; Godena VK; Whitworth AJ
    Hum Mol Genet; 2015 Nov; 24(21):6106-17. PubMed ID: 26251041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.